TrialClinical and experimental nephrology2025
Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial.
Eiji Higashihara et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.